The European Medicines Agency (EMA) on April 8, 2026, published a proposal to strengthen veterinary drug safety monitoring through new expert recommendations, targeting veterinary pharmaceutical companies, national competent authorities, veterinarians, and animal owners. The document, issued by EMA's Veterinary Medicines Division, is a formal recommendation that includes specific suggestions for improving adverse event reporting, risk management plans, and post-marketing surveillance for veterinary medicinal products.
Document Context and Type The proposal, titled 'EMA Proposes Enhanced Veterinary Drug Safety Monitoring Through Expert Recommendations,' is a non-binding recommendation that builds on the agency's ongoing efforts to improve pharmacovigilance. It follows the EMA Pharmacovigilance Committee's adoption of new drug safety monitoring recommendations on April 7, 2026, which focused on human medicines. The new veterinary proposal extends similar principles to animal health, calling for standardized electronic reporting formats and closer collaboration with veterinary professional organizations.
Policy Orientations and Trade-offs The proposal balances enhanced safety oversight with the need to avoid disproportionate administrative burden on veterinary practices and small pharmaceutical companies. It recommends mandatory training for veterinarians on adverse event reporting but stops short of requiring real-time reporting systems. The trade-off involves increased data collection costs versus improved early detection of safety issues in animals and potentially humans through the food chain.
Impact on Stakeholders - Veterinary pharmaceutical companies: Moderate positive impact from clearer safety monitoring guidelines, but negative impact from potential increased compliance costs for updating risk management plans and reporting systems. - National competent authorities: Positive impact from standardized reporting formats facilitating cross-border data comparison, but negative impact from need to train staff and adapt national systems. - Veterinarians: Negative impact from mandatory training requirements and additional paperwork, but positive impact from improved access to safety data. - Animal owners and consumers: Positive impact from enhanced safety of veterinary medicines and reduced risk of residues in food products.
Expected Institutional Follow-up The EMA will now seek feedback from stakeholders through a public consultation period ending June 8, 2026. The final recommendations are expected to be adopted by the Committee for Veterinary Medicinal Products later this year and may influence future revisions of EU veterinary pharmacovigilance legislation.
← Atlas › News › Health & Lifestyle